The firm will use the agreement to access alternative non-dilutive means of financing of its growth plans.
The company, which has just changed its name from Sygnis, has now completed the integration of several recent acquisitions including TGR Biosciences.
The company anticipates 2018 revenues in the range of €11 million to €12 million, excluding the impact of recently acquired TGR Biosciences.
TGR's proprietary protein capturing technology is expected to complement Sygnis' range of immunology, genomic, and proteomic products and services.
The company had intended to raise up to €6.6 million through the placement to help fund its planned acquisition of TGR Biosciences.
Sygnis said that TGR is profitable and has a complementary product portfolio that includes protein capture technology.
The New York Times reports that the US Department of Defense has implemented about half the recommendations made to improve safe handling of dangerous agents.
An Australian-led team has generated a draft genome assembly of the invasive cane toad in hopes it will help in population control, the Sydney Morning Herald reports.
In PLOS this week: approach for teasing out archaic introgression in human genomes, immune transcription features in HCV infection, and more.
Stat News reports that Maryland is promoting itself to the biotech industry with a mobile billboard.